352 related articles for article (PubMed ID: 22031948)
1. Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection.
Kong R; Li H; Bibollet-Ruche F; Decker JM; Zheng NN; Gottlieb GS; Kiviat NB; Sow PS; Georgiev I; Hahn BH; Kwong PD; Robinson JE; Shaw GM
J Virol; 2012 Jan; 86(2):947-60. PubMed ID: 22031948
[TBL] [Abstract][Full Text] [Related]
2. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
3. Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infection across a broad range of infection outcomes.
de Silva TI; Aasa-Chapman M; Cotten M; Hué S; Robinson J; Bibollet-Ruche F; Sarge-Njie R; Berry N; Jaye A; Aaby P; Whittle H; Rowland-Jones S; Weiss R
J Virol; 2012 Jan; 86(2):930-46. PubMed ID: 22072758
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
[TBL] [Abstract][Full Text] [Related]
5. Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies.
Kong R; Li H; Georgiev I; Changela A; Bibollet-Ruche F; Decker JM; Rowland-Jones SL; Jaye A; Guan Y; Lewis GK; Langedijk JP; Hahn BH; Kwong PD; Robinson JE; Shaw GM
J Virol; 2012 Nov; 86(22):12115-28. PubMed ID: 22933274
[TBL] [Abstract][Full Text] [Related]
6. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
7. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.
deCamp A; Hraber P; Bailer RT; Seaman MS; Ochsenbauer C; Kappes J; Gottardo R; Edlefsen P; Self S; Tang H; Greene K; Gao H; Daniell X; Sarzotti-Kelsoe M; Gorny MK; Zolla-Pazner S; LaBranche CC; Mascola JR; Korber BT; Montefiori DC
J Virol; 2014 Mar; 88(5):2489-507. PubMed ID: 24352443
[TBL] [Abstract][Full Text] [Related]
8. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.
Davis KL; Gray ES; Moore PL; Decker JM; Salomon A; Montefiori DC; Graham BS; Keefer MC; Pinter A; Morris L; Hahn BH; Shaw GM
Virology; 2009 May; 387(2):414-26. PubMed ID: 19298995
[TBL] [Abstract][Full Text] [Related]
9. Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma.
Davis KL; Bibollet-Ruche F; Li H; Decker JM; Kutsch O; Morris L; Salomon A; Pinter A; Hoxie JA; Hahn BH; Kwong PD; Shaw GM
J Virol; 2009 Feb; 83(3):1240-59. PubMed ID: 19019969
[TBL] [Abstract][Full Text] [Related]
10. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
Wu X; Wang C; O'Dell S; Li Y; Keele BF; Yang Z; Imamichi H; Doria-Rose N; Hoxie JA; Connors M; Shaw GM; Wyatt RT; Mascola JR
J Virol; 2012 May; 86(10):5844-56. PubMed ID: 22419808
[TBL] [Abstract][Full Text] [Related]
11. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
[TBL] [Abstract][Full Text] [Related]
12. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.
Kong R; Louder MK; Wagh K; Bailer RT; deCamp A; Greene K; Gao H; Taft JD; Gazumyan A; Liu C; Nussenzweig MC; Korber B; Montefiori DC; Mascola JR
J Virol; 2015 Mar; 89(5):2659-71. PubMed ID: 25520506
[TBL] [Abstract][Full Text] [Related]
13. Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection.
Ringe R; Thakar M; Bhattacharya J
Retrovirology; 2010 Sep; 7():76. PubMed ID: 20860805
[TBL] [Abstract][Full Text] [Related]
14. CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies.
Gardner MR; Fellinger CH; Prasad NR; Zhou AS; Kondur HR; Joshi VR; Quinlan BD; Farzan M
J Virol; 2016 Sep; 90(17):7822-32. PubMed ID: 27334589
[TBL] [Abstract][Full Text] [Related]
15. Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development.
Malherbe DC; Wibmer CK; Nonyane M; Reed J; Sather DN; Spencer DA; Schuman JT; Guo B; Pandey S; Robins H; Park B; Fuller DH; Sacha JB; Moore PL; Hessell AJ; Haigwood NL
Front Immunol; 2020; 11():984. PubMed ID: 32582155
[TBL] [Abstract][Full Text] [Related]
16. Genetic and neutralization properties of HIV-1 env clones from subtype B/BC/AE infections in China.
Chong H; Hong K; Zhang C; Nie J; Song A; Kong W; Wang Y
J Acquir Immune Defic Syndr; 2008 Apr; 47(5):535-43. PubMed ID: 18209676
[TBL] [Abstract][Full Text] [Related]
17. Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.
Hraber P; Rademeyer C; Williamson C; Seaman MS; Gottardo R; Tang H; Greene K; Gao H; LaBranche C; Mascola JR; Morris L; Montefiori DC; Korber B
J Virol; 2017 Oct; 91(19):. PubMed ID: 28747500
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
[TBL] [Abstract][Full Text] [Related]
19. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
Li H; Zony C; Chen P; Chen BK
J Virol; 2017 May; 91(9):. PubMed ID: 28148796
[TBL] [Abstract][Full Text] [Related]
20. Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth.
Chukwuma VU; Kose N; Sather DN; Sapparapu G; Falk R; King H; Singh V; Lampley R; Malherbe DC; Ditto NT; Sullivan JT; Barnes T; Doranz BJ; Labranche CC; Montefiori DC; Kalams SA; Haigwood NL; Crowe JE
PLoS One; 2018; 13(12):e0209437. PubMed ID: 30566528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
